collaboration Jan 11, 2023 Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms Jan 10, 2023 Sophia Genetics to Commercialize MSK-ACCESS Clinical Liquid Biopsy Test Jan 9, 2023 Caris Life Sciences, ConcertAI Partner on Molecular Oncology R&D Platform Jan 9, 2023 Genentech Offers Kronos Bio up to $554M in Deal to Discover Drugs Against Transcription Factors Jan 9, 2023 GreenLight Biosciences, EpiVax Therapeutics Partner to Develop Personalized Cancer Vaccines Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Jan 6, 2023 In Brief This Week: Datar Cancer Genetics, Daiichi Sankyo, ProPhase Labs, Innovent Biologics Jan 5, 2023 Frontier Medicines Selects KRAS G12C Inhibitor as Lead Development Candidate Jan 5, 2023 Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer Jan 4, 2023 Nuvectis Partners With ENGOT, GOG Foundation on Phase Ib Ovarian Cancer Trial of HSF1 Inhibitor Dec 22, 2022 Merck Pays $175M Upfront for Rights to Seven Kelun-Biotech Antibody-Drug Conjugate Candidates Dec 21, 2022 Jazz Takes Up Option on Zymeworks' HER2-Targeted Bispecific Antibody Dec 20, 2022 Gilead Sciences to Acquire Cell Therapy Biotech Tmunity Therapeutics Dec 20, 2022 Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 19, 2022 Ordaōs, Yatiri Bio Ink Deal to Discover, Develop More Personalized Drugs for AML Dec 19, 2022 Carrick Therapeutics, Menarini Group Studying Samuraciclib With Elacestrant Dec 16, 2022 Everything Genetic, Berkshire and Surrey Pathology Services Jointly Launch Cancer NGS Service in UK Dec 14, 2022 NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform Dec 9, 2022 Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer